BACKGROUND: The Jetstream device is an effective treatment option for debulking calcified lesions
however, it carries a risk of damaging the healthy vessel wall. This study aimed to evaluate the safety and efficacy of the Jetstream device combined with wire bias adjustments for treating eccentric calcified lesions. AIMS: The aim of this study was to evaluate the safety and efficacy of JET EDGE technique for treating eccentric calcified lesions. METHODS: This single-center, retrospective, nonrandomized observational study was conducted at a cardiovascular department in Japan. It included patients aged ≥ 20 years with eccentric calcified lesions (Rutherford classification 3-6) who underwent endovascular therapy using the Jetstream catheter for femoropopliteal disease between October 2022 and September 2024. RESULTS: Twenty-eight lesions in 28 patients (28.6% female
mean age: 76.9 ± 7.3 years) with a mean follow-up period of 409 ± 174 days were analyzed. All lesions were graded 3 or 4 on the peripheral arterial calcium scoring system. The procedural success rate was 96.4%. No vascular perforations or medial layer damage were observed on imaging following the use of the Jetstream catheter. The 1-year Kaplan-Meier estimates for primary patency, freedom from major adverse limb events, and freedom from target lesion revascularization were 88.6%, 88.1%, and 91.3%, respectively. CONCLUSIONS: This retrospective study demonstrates that eccentric calcified lesions, which pose a risk of damaging the healthy vessel wall during treatment with the Jetstream catheter, can be safely treated by adjusting the wire bias during the procedure.